SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 10.58 |
| Enterprise Value ($M) | 7.03 |
| Book Value ($M) | 29.83 |
| Book Value / Share | 4.85 |
| Price / Book | 0.35 |
| NCAV ($M) | -25.27 |
| NCAV / Share | -4.11 |
| Price / NCAV | -0.42 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.13 |
| Return on Assets (ROA) | -0.05 |
| Return on Equity (ROE) | -0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.80 |
| Current Ratio | 0.99 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 60.74 |
| Assets | 115.83 |
| Liabilities | 86.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 81.00 |
| Operating Income | -2.16 |
| Net Income | -15.84 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -1.39 |
| Cash from Investing | -0.33 |
| Cash from Financing | -1.26 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Stonepine Capital Management, LLC | 9.99 | 10.85 | |
| 13D/A | Nantahala Capital Management, LLC | 18.20 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 782 | 13,963 | 5.60 | |
| 3,442 | 9,794 | 35.14 | |
| 77 | 3,937 | 1.96 | |
| 4,420 | 39,793 | 11.11 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ATYR – aTyr Pharma, Inc. | AVTX – Avalo Therapeutics, Inc. |
| AWH – Aspira Women's Health Inc. | BCDA – BioCardia, Inc. |
| BCLI – Brainstorm Cell Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io